These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16539085)

  • 1. Estimation of the average causal effect among subgroups defined by post-treatment variables.
    Matsuyama Y; Morita S
    Clin Trials; 2006; 3(1):1-9. PubMed ID: 16539085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kaplan-Meier curves for survivor causal effects with time-to-event outcomes.
    Chiba Y
    Clin Trials; 2013 Aug; 10(4):515-21. PubMed ID: 23610455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data.
    Lou Y; Jones MP; Sun W
    J Biopharm Stat; 2019; 29(1):151-173. PubMed ID: 29995564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple Estimation of Patient-Oriented Effects From Randomized Trials: An Open and Shut CACE.
    Steele RJ; Shrier I; Kaufman JS; Platt RW
    Am J Epidemiol; 2015 Sep; 182(6):557-66. PubMed ID: 26283090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of the effect of interventions that modify the received treatment.
    Haneuse S; Rotnitzky A
    Stat Med; 2013 Dec; 32(30):5260-77. PubMed ID: 23913589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events.
    Lou Y; Jones MP; Sun W
    Stat Med; 2019 Nov; 38(27):5214-5235. PubMed ID: 31621943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the treatment effect for adherers using multiple imputation.
    Luo J; Ruberg SJ; Qu Y
    Pharm Stat; 2022 May; 21(3):525-534. PubMed ID: 34927339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarifying selection bias in cluster randomized trials.
    Li F; Tian Z; Bobb J; Papadogeorgou G; Li F
    Clin Trials; 2022 Feb; 19(1):33-41. PubMed ID: 34894795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple efficient bias corrected instrumental variable estimator for randomized trials with noncompliance.
    Chan KC
    Contemp Clin Trials; 2012 Jul; 33(4):786-93. PubMed ID: 22484340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive truncated weighting for improving marginal structural model estimation of treatment effects informally censored by subsequent therapy.
    Bai X; Liu J; Li L; Faries D
    Pharm Stat; 2015; 14(6):448-54. PubMed ID: 26436533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A general implementation of TMLE for longitudinal data applied to causal inference in survival analysis.
    Stitelman OM; De Gruttola V; van der Laan MJ
    Int J Biostat; 2012 Sep; 8(1):. PubMed ID: 22992289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclassification estimation of the weighted average treatment effect.
    Choi BY
    Biom J; 2021 Dec; 63(8):1706-1728. PubMed ID: 34270815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Instruments and bounds for causal effects under the monotonic selection assumption.
    Taguri M; Chiba Y
    Int J Biostat; 2012 Aug; 8(1):24. PubMed ID: 22944723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Centered Hazard Ratio Estimation Using Principal Stratification Weights: Application to the NORCCAP Randomized Trial of Colorectal Cancer Screening.
    MacKenzie TA; Løberg M; O'Malley AJ
    Obs Stud; 2016 Mar; 2():29-50. PubMed ID: 29644344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of causal effects of binary treatments in unconfounded studies.
    Gutman R; Rubin DB
    Stat Med; 2015 Nov; 34(26):3381-98. PubMed ID: 26013308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of trial duration on the bias of the estimated treatment effect in clinical trials when individual heterogeneity is ignored.
    Cécilia-Joseph E; Auvert B; Broët P; Moreau T
    Biom J; 2015 May; 57(3):371-83. PubMed ID: 25597640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimators and confidence intervals for the marginal odds ratio using logistic regression and propensity score stratification.
    Stampf S; Graf E; Schmoor C; Schumacher M
    Stat Med; 2010 Mar; 29(7-8):760-9. PubMed ID: 20213703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilizing propensity scores to estimate causal treatment effects with censored time-lagged data.
    Anstrom KJ; Tsiatis AA
    Biometrics; 2001 Dec; 57(4):1207-18. PubMed ID: 11764262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
    Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
    Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bias analysis of the instrumental variable estimator as an estimator of the average causal effect.
    Chiba Y
    Contemp Clin Trials; 2010 Jan; 31(1):12-7. PubMed ID: 19879376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.